Fig. 3

MYEOV overexpression in pancreatic cancer cell lines. A, cDNA was synthesized from RNA derived from commercially available normal pancreatic tissues or RNA extracted from the five pancreatic cancer cell lines shown in the figure, and the levels of MYEOV mRNA were quantified by qPCR. The MYEOV mRNA level in normal pancreatic tissues normalized to TBP mRNA was set to 1, and the relative MYEOV expression levels in pancreatic cancer cell lines are shown. B, Changes in MYEOV mRNA expression in the MiaPaCa-2 cell line treated with 5-Aza-dC. Cells were treated with 5-Aza-dC or DMSO for 7 days, and mRNA levels were quantified by qPCR. The amount of MYEOV mRNA in each sample was normalized to the amount of GAPDH mRNA, and the relative MYEOV expression levels are shown in the graph with the DMSO-treated sample as 1. C, BxPC3 and SUIT-2 cells were transfected with 10 nM control or MYEOV-targeting siRNAs, and the knockdown efficiency was measured by qPCR using MYEOV-specific primers. MYEOV expression levels are shown in the graph with the nonspecific control siRNA-treated sample as 1. Black bars indicate cells transfected with control siRNA, and red and green bars represent cells transfected with MYEOV-specific siRNA. D, Cellular proliferation upon knockdown of MYEOV was measured by a real-time GLO growth assay at the indicated time points. The results are expressed as the fold change (mean ± SD, n = 4) compared to the respective values of control cells (day 0)